AI Research Answer
What are the underlying pathophysiological mechanisms that differentiate primary FSGS from secondary FSGS, and how do these differences justify distinct treatment approaches?
3 cited papers · March 31, 2026 · Powered by Researchly AI
🧠
TL;DR
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria and frequent progression to end-stage renal disease. Primary FSGS…
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria and frequent progression to end-stage renal disease.1Chen & Liapis (2015)1Primary FSGS is increasingly understood as a primary podocytopathy driven by specific genetic mutations and circulating permeability factors, while secondary FSGS arises from distinct upstream insults — a distinction with direct therapeutic implications.2
1
Focal segmental glomerulosclerosis: molecular genetics and targeted therapiesYing Maggie Chen, Helen Liapis2015BMC Nephrology
View 2
Recent Progress in the Pathophysiology and Treatment of FSGS RecurrencePaolo Cravedi, Jeffrey B. Kopp et al.2013American Journal of Transplantation
View - Podocyte injury — The central pathological event in FSGS; podocyte foot processes undergo effacement, losing structure and spreading out, leading to reduced filtration barrier function and proteinuria.
- Genetic/primary podocytopathy — Primary FSGS is caused by podocyte-specific gene mutations including NPHS1, NPHS2, WT-1, LAMB2, CD2AP, TRPC6, ACTN4, and INF2, disrupting the slit diaphragm and actin cytoskeleton.
- Circulating permeability factors — In non-genetic primary FSGS, experimental and clinical evidence supports the existence of circulating factors capable of damaging podocytes, though no single causal molecule has been consistently identified. Cravedi et al. (2013)
- Glomerular filtration barrier — Composed of podocyte foot processes, the slit diaphragm, and the glomerular basement membrane (GBM); disruption of focal adhesion complexes that bind podocytes to the GBM leads to detachment and progressive sclerosis.
Löwik et al. (2009)
2
Focal segmental glomerulosclerosis: molecular genetics and targeted therapiesYing Maggie Chen, Helen Liapis2015BMC Nephrology
View 3
Recent Progress in the Pathophysiology and Treatment of FSGS RecurrencePaolo Cravedi, Jeffrey B. Kopp et al.2013American Journal of Transplantation
View Want to research your own topic? Try it free →
Diagram
PRIMARY FSGS PATHWAY ===================== [Genetic Mutation] [Circulating Permeability Factor] NPHS1/NPHS2/TRPC6/ (T-cell / B-cell abnormality?) ACTN4/INF2/WT1 etc. | | | v v [Slit Diaphragm Disruption] <--- [Podocyte Surface Receptor Damage] | v [Actin Cytoskeleton Breakdown] | v [Foot Process Effacement] | v [Loss of Filtration Barrier] | v [Proteinuria] --> [Podocyte Depletion] --> [Glomerular Sclerosis] | v [End-Stage Renal Disease] SECONDARY FSGS PATHWAY ======================= [Upstream Insult] (Obesity / Hypertension / Viral infection / Drug toxicity / Reduced nephron mass) | v [Glomerular Hyperfiltration / Hypertrophy] | v [Mechanical Stress on Podocytes] | v [Adaptive Podocyte Injury] | v [Foot Process Effacement (partial)] | v [Proteinuria (typically milder)] --> [Progressive Sclerosis] TREATMENT DIVERGENCE ==================== Primary FSGS Secondary FSGS ───────────────── ────────────────────── Immunosuppression Treat underlying cause (Cyclosporine, steroids) (BP control, weight loss) Plasmapheresis (if RAS antagonists circulating factor suspected) (antiproteinuric agents) Targeted molecular therapy Nephron-protective strategies (NGS-guided, mutation-specific)
Table
| Feature | Primary FSGS | Secondary FSGS |
|---|---|---|
| Primary driver | Podocyte gene mutations or circulating permeability factors | Systemic/adaptive insults (hyperfiltration, toxins, viruses) |
| Immune involvement | T-cell and possibly B-cell abnormalities implicated | Typically non-immune mechanical/metabolic stress |
| Genetic basis | NPHS1, NPHS2, TRPC6, ACTN4, INF2, WT1, LAMB2, CD2AP | Usually polygenic susceptibility, not monogenic |
| Recurrence post-transplant | ~25% recurrence rate, driven by circulating factors | Rare recurrence unless systemic disease persists |
| First-line treatment | Plasmapheresis + high-dose cyclosporine; NGS-guided targeted therapy | RAS antagonists, antiproteinuric agents, address underlying cause |
Abnormalities in T and possibly B cells may represent one initial pathogenic trigger in primary FSGS, leading to podocyte injury and progressive loss.1Next-generation sequencing (NGS) now promises rapid and novel diagnostic approaches, enabling a stratified and targeted treatment strategy based on the underlying molecular defect.2Despite strong evidence that antiproteinuric agents slow renal function decline, maximal use of renin-angiotensin system (RAS) antagonists is not yet routine in FSGS recurrence management.1
1
Recent Progress in the Pathophysiology and Treatment of FSGS RecurrencePaolo Cravedi, Jeffrey B. Kopp et al.2013American Journal of Transplantation
View 2
Focal segmental glomerulosclerosis: molecular genetics and targeted therapiesYing Maggie Chen, Helen Liapis2015BMC Nephrology
View Want to research your own topic? Try it free →
The evidence base has a critical gap: no single circulating molecule has been consistently identified as the causal pathogenic element in FSGS recurrence, limiting the development of targeted therapies for immune-mediated primary FSGS.1Furthermore, while genetic studies have identified numerous podocyte gene mutations, the functional role of many newly discovered genes remains incompletely characterized, and the translation from mechanistic discoveries to improved patient outcomes has been slow.2
1
Recent Progress in the Pathophysiology and Treatment of FSGS RecurrencePaolo Cravedi, Jeffrey B. Kopp et al.2013American Journal of Transplantation
View 2
Focal segmental glomerulosclerosis: molecular genetics and targeted therapiesYing Maggie Chen, Helen Liapis2015BMC Nephrology
View - Podocyte foot process effacement and loss of the slit diaphragm filtration barrier are the shared final pathway in both primary and secondary FSGS, but the upstream triggers differ fundamentally.
- Primary FSGS is driven by specific podocyte gene mutations (NPHS1, NPHS2, TRPC6, etc.) or circulating permeability factors, justifying immunosuppressive and molecularly targeted therapies.
- Circulating permeability factors — likely involving T-cell and B-cell dysregulation — explain the ~25% recurrence rate of primary FSGS after kidney transplantation.
- Plasmapheresis and high-dose cyclosporine remain the mainstays of therapy for primary FSGS recurrence, reflecting the circulating-factor hypothesis.
- NGS-guided molecular diagnosis is evolving as the cornerstone of a stratified, mutation-specific treatment approach for genetic FSGS.
2
Focal segmental glomerulosclerosis: molecular genetics and targeted therapiesYing Maggie Chen, Helen Liapis2015BMC Nephrology
View 3
Recent Progress in the Pathophysiology and Treatment of FSGS RecurrencePaolo Cravedi, Jeffrey B. Kopp et al.2013American Journal of Transplantation
View Want to research your own topic? Try it free →
- "NPHS2 podocin mutation steroid resistance nephrotic syndrome treatment outcomes" — to explore genotype-specific therapeutic responses in genetic FSGS
- "Circulating permeability factor FSGS suPAR identification biomarker" — to investigate candidate molecules driving primary FSGS recurrence post-transplant
- "Secondary FSGS hyperfiltration obesity renin-angiotensin system nephroprotection" — to understand the mechanistic basis and treatment of adaptive/secondary FSGS
Research smarter with AI-powered citations
Researchly finds and cites academic papers for any research topic in seconds. Used by students across India.